ReviewTherapeutic advances in gastroenterology2018
Emerging concepts in non-invasive monitoring of Crohn's disease.
Review in Therapeutic advances in gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Diagnostic value of MR and CT enterography in post-operative recurrence of Crohn's disease: a systematic review and meta-analysis.Abdominal radiology (New York) · 2024Pooled it
- Diagnostic and clinical significance of antigen-specific pancreatic antibodies in inflammatory bowel diseases: A meta-analysis.World journal of gastroenterology · 2020Pooled it
- Emerging role of intestinal ultrasound in detecting postoperative recurrence in Crohn's disease.Gastroenterology report · 2026Review
- Gut microbiome-driven mechanisms in inflammatory bowel disease-associated interstitial lung disease: from dysbiosis to therapeutic implications.Frontiers in cellular and infection microbiology · 2026Review
- Article
- The impact of artificial intelligence on the endoscopic assessment of inflammatory bowel disease-related neoplasia.Therapeutic advances in gastroenterology · 2025Review
- Exploring Maternal Diet-Epigenetic-Gut Microbiome Crosstalk as an Intervention Strategy to Counter Early Obesity Programming.Current issues in molecular biology · 2024Review
- Hydrogen gas and the gut microbiota are potential biomarkers for the development of experimental colitis in mice.Gut microbiome (Cambridge, England) · 2024Article
- Artificial intelligence and inflammatory bowel disease: Where are we going?World journal of gastroenterology · 2023Review
- Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease.Therapeutic advances in gastroenterology · 2023Article
- Circulating Extracellular Vesicles Are Increased in Newly Diagnosed Celiac Disease Patients.Nutrients · 2022Article
- Peripheral Blood DNA Methylation Profiles Do Not Predict Endoscopic Post-Operative Recurrence in Crohn's Disease Patients.International journal of molecular sciences · 2022Article
- Probiotics, prebiotics and synbiotics: Safe options for next-generation therapeutics.Applied microbiology and biotechnology · 2022Review
- Role of Digital Health and Artificial Intelligence in Inflammatory Bowel Disease: A Scoping Review.Genes · 2021Article
- Inflammatory Bowel Disease and Neutrophil-Lymphocyte Ratio: A Systematic Scoping Review.Journal of clinical medicine · 2021Article
- Dynamic Process of Secondary Pulmonary Infection in Mice With Intracerebral Hemorrhage.Frontiers in immunology · 2021Article
- The Multifactorial Etiopathogeneses Interplay of Inflammatory Bowel Disease: An Overview.Gastrointestinal disorders (Basel, Switzerland) · 2019Article
- The Epigenetic Connection Between the Gut Microbiome in Obesity and Diabetes.Frontiers in genetics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is an umbrella term for Crohn's disease (CD) and ulcerative colitis (UC). In light of evolving epidemiology of CD, its clinical management is still complex and remains a challenge for contemporary physicians. With the advent of new diagnostic and treatment paradigms, there is a growing need for new biomarkers to guide decision-making, differential diagnosis, disease activity monitoring, as well as prognosis. However, both clinical and endoscopic scoring systems, widely utilized for disease monitoring and prognosis, have drawbacks and limitations. In recent years, biochemical peptides have become available for IBD monitoring and more frequently used as surrogate markers of gut inflammation. Emerging concepts that revolve around molecular, stem cell, epigenetic, microbial or metabolomic pathways associated with vascular and epithelial gut barrier could lead to development of new CD biomarkers. Measurement of cell-derived microvesicles (MVs) in the blood of IBD patients is another emerging concept helpful in future disease management. In this review, we discuss novel concepts of non-invasive biomarkers, which may become useful in monitoring of CD activity and prognosis. We discuss metabolomics as a new powerful tool for clinicians to guide differential IBD diagnosis. In the coming years, new developments of prognostic tools are expected, aiming for breakthroughs in the management of patients with CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.